ii) a VL CDR2 having the amino acid sequence of SEQ ID NO:5 and

iii) a VL CDR3 having the amino acid sequence of SEQ ID NO:6;

or

c) an antibody VH domain comprising:

i) a VH CDR1 having the amino acid sequence of SEQ ID NO:13,

ii) a VH CDR2 having the amino acid sequence of SEQ ID NO:14 and

iii) a VH CDR3 having the amino acid sequence of SEQ ID NO:15,

and

d) an antibody VL domain comprising:

i) a VL CDR1 having the amino acid sequence of SEQ ID NO:16,

ii) a VL CDR2 having the amino acid sequence of SEQ ID NO:17 and

iii) a VL CDR3 having the amino acid sequence of SEQ ID NO:18,

and the antibody fragment comprises an antigen binding region that binds to VISTA~~, thereby enhancing an immune response to the cancer~~.

~~106.~~ (Canceled) ~~The use of Claim 105, wherein the immune response is an antitumor immune response.~~

~~107~~ 43. ~~(Amended)~~ The use of an antibody or an antibody fragment thereof in the manufacture of a medicament ~~of eliciting a biological response~~ for treating cancer in an individual in need thereof, wherein the antibody binds V-domain Ig Suppressor of T cell Activation (VISTA) and comprises:

a) an antibody VH domain comprising:

i) a VH CDR1 having the amino acid sequence of SEQ ID NO:1,

ii) a VH CDR2 having the amino acid sequence of SEQ ID NO:2 and

iii) a VH CDR3 having the amino acid sequence of SEQ ID NO:3,

and

b) an antibody VL domain comprising:

i) a VL CDR1 having the amino acid sequence of SEQ ID NO:4,

ii) a VL CDR2 having the amino acid sequence of SEQ ID NO:5 and

iii) a VL CDR3 having the amino acid sequence of SEQ ID NO:6;

or

c) an antibody VH domain comprising:

i) a VH CDR1 having the amino acid sequence of SEQ ID NO:13,

ii) a VH CDR2 having the amino acid sequence of SEQ ID NO:14 and

iii) a VH CDR3 having the amino acid sequence of SEQ ID NO:15,

and

d) an antibody VL domain comprising:

i) a VL CDR1 having the amino acid sequence of SEQ ID NO:16,

ii) a VL CDR2 having the amino acid sequence of SEQ ID NO:17 and

iii) a VL CDR3 having the amino acid sequence of SEQ ID NO:18,

and the antibody fragment comprises an antigen binding region that binds to VISTA~~, thereby enhancing an immune response to the cancer~~, wherein the

antibody or antibody fragment elicits a biological response is selected from the group consisting of:

a. activation of monocytes;

b. induction of T-cell proliferation and cytokine secretion;

c. increased survival of monocytes;

d. induction of antibody-dependent cell-mediated cytotoxicity (ADCC) in cells-expressing VISTA; and

e. induction of antibody-dependent cellular phagocytosis (ADCP) in cells-expressing VISTA.

~~108.~~ (Canceled) ~~An isolated antibody or antibody fragment thereof that competitively inhibits binding of the antibody or antibody fragment of Claim 1 to human VISTA (SEQ ID NO:46).~~

~~109.~~ ~~(New)~~ An antibody or antibody fragment according to claim ~~12~~ or ~~18~~, wherein at least one heavy chain comprises the heavy chain sequence as shown in SEQ ID NO:47, and wherein at least one light chain comprises the light chain sequence as shown in SEQ ID NO:48.

~~110.~~ ~~(New)~~ An antibody or antibody fragment according to claim ~~12~~, wherein at least one heavy chain comprises the heavy chain sequence as shown in SEQ ID NO:51, and wherein at least one light chain comprises the light chain sequence as shown in SEQ ID NO:52.

~~111.~~ ~~(New)~~ The use of any one of claims ~~53-67, 105~~ and ~~107~~, wherein the antibody comprises the heavy chain variable region sequence as shown in SEQ ID NO:38, and the light chain variable region sequence as shown in SEQ ID NO: 41.

~~112.~~ ~~(New)~~ The use of any one of claims ~~53-67, 105, 107 and 111~~, wherein the antibody comprises the heavy chain sequence as shown in SEQ ID NO:47, and the light chain sequence as shown in SEQ ID NO:48.